{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:09:41Z","timestamp":1764133781096,"version":"3.40.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,28]]},"DOI":"10.7759\/cureus.81364","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T16:26:56Z","timestamp":1743179216000},"source":"Crossref","is-referenced-by-count":1,"title":["Unveiling Risankizumab\u2019s Rare Side Effect: A Case of Severe Thrombocytopenia in Psoriatic Arthritis"],"prefix":"10.7759","author":[{"given":"Jinalben","family":"Chaudhari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dighe R","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.153","article-title":"Drug-induced thrombocytopenia: pathogenesis, evaluation, and management","author":"George JN","year":"2009","unstructured":"George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program. 2009, 153-8. 10.1182\/asheducation-2009.1.153","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster RH","year":"2007","unstructured":"Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007, 357:580-7. 10.1056\/NEJMra066469","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201810001-02044","article-title":"Ustekinumab-associated thrombocytopenia in a patient with refractory Crohn\u2019s disease: 2044","volume":"113","author":"Levine I","year":"2018","unstructured":"Levine I, Rolston V, Papademetriou M, Malter L. Ustekinumab-associated thrombocytopenia in a patient with refractory Crohn\u2019s disease: 2044. Am J Gastroenterol. 2018, 113:","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1041884","article-title":"Case report: severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: a case report and literature review","volume":"13","author":"Liao T","year":"2022","unstructured":"Liao T, Li M, Yuan T, et al.. Case report: severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: a case report and literature review. Front Pharmacol. 2022, 13:1041884. 10.3389\/fphar.2022.1041884","journal-title":"Front Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04896-7","article-title":"Hematologic side effects of biologics and kinase inhibitors used in rheumatologic diseases: a review of the current evidence","volume":"101","author":"Bhandari S","year":"2022","unstructured":"Bhandari S, Baral MR, Barbery M, Rudinskaya A, Sostin O. Hematologic side effects of biologics and kinase inhibitors used in rheumatologic diseases: a review of the current evidence. Ann Hematol. 2022, 101:1897-904. 10.1007\/s00277-022-04896-7","journal-title":"Ann Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-015-0022-7","article-title":"Differential adverse events between TNF-\u03b1 inhibitors and IL-17 axis inhibitors for the treatment of spondyloarthritis","volume":"1","author":"Antonelli M","year":"2015","unstructured":"Antonelli M, Khan MA, Magrey MN. Differential adverse events between TNF-\u03b1 inhibitors and IL-17 axis inhibitors for the treatment of spondyloarthritis. Curr Treat Options Rheum. 2015, 1:239-54. 10.1007\/s40674-015-0022-7","journal-title":"Curr Treat Options Rheum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_407_18","article-title":"Biologics in dermatology: off-label indications","volume":"11","author":"Mitra D","year":"2020","unstructured":"Mitra D, Chopra A, Saraswat N, Mitra B, Talukdar K, Agarwal R. Biologics in dermatology: off-label indications. Indian Dermatol Online J. 2020, 11:319-27. 10.4103\/idoj.IDOJ_407_18","journal-title":"Indian Dermatol Online J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention\u00a0strategy","volume":"31","author":"Haanen J","year":"2020","unstructured":"Haanen J, Ernstoff MS, Wang Y, et al.. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention\u00a0strategy. Ann Oncol. 2020, 31:724-44. 10.1016\/j.annonc.2020.03.285","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/310018-unveiling-risankizumabs-rare-side-effect-a-case-of-severe-thrombocytopenia-in-psoriatic-arthritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T16:26:58Z","timestamp":1743179218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/310018-unveiling-risankizumabs-rare-side-effect-a-case-of-severe-thrombocytopenia-in-psoriatic-arthritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.81364","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}